PET/MRI in the Diagnosis of Chronic Pain
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03556137 |
Recruitment Status :
Recruiting
First Posted : June 14, 2018
Last Update Posted : July 2, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Neuropathic Pain Nociceptive Pain MIxed Pain (Nociceptive and Neuropathic) | Drug: [18F]FTC-146 | Phase 1 |
Chronic pain is a significant, widespread problem affecting every fifth person worldwide. Reported in 2011 by the Institute of Medicine, chronic pain affects 116 million American adults - more than the total number of individuals affected by heart disease, cancer, and diabetes combined. An estimated $635 billion each year is spent in the medical management of chronic pain and lost productivity. Better clinical methods to diagnose and localize pain are needed.
The investigators have developed a S1R-specific radiotracer, [18F]FTC-146. Using imaging approaches to assess the location of S1R in pain may provide a tool to diagnose pain generators, monitor treatment response, and aid in the selection of patients for treatment.
The goal is to use [18F]FTC-146 to image S1R expression in healthy volunteers and to compare the images to those individuals suffering from pain conditions in the following categories: (1) nociceptive pain (pain that results from tissue injury or inflammation), (2) neuropathic pain (pain that results from direct injury, disruption, impingement/compression or malfunction of the peripheral and/or central nervous system), and (3) mixed pain (pain that appears to have both nociceptive and neuropathic).
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 144 participants |
Allocation: | Non-Randomized |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Diagnostic |
Official Title: | Use of [18F]FTC-146 PET/MRI in the Diagnosis of Chronic Pain |
Actual Study Start Date : | July 16, 2018 |
Estimated Primary Completion Date : | June 2023 |
Estimated Study Completion Date : | June 2024 |

Arm | Intervention/treatment |
---|---|
Experimental: Pain Patients
Individuals suffering from nociceptive pain, neuropathic pain, and mixed pain (pain that appears to be both nociceptive and neuropathic) and undergo a [18F]FTC-146 PET/MRI scan.
|
Drug: [18F]FTC-146
Adult participants will be injected with 5-10 mCi of [18F]FTC-146 and undergo a PET/MRI scan.
Other Name: S1R |
Experimental: Healthy Volunteers
Individuals who do not have pain and undergo a [18F]FTC-146 PET/MRI scan.
|
Drug: [18F]FTC-146
Adult participants will be injected with 5-10 mCi of [18F]FTC-146 and undergo a PET/MRI scan.
Other Name: S1R |
- [18F]FTC-146 Biodistribution in Healthy Volunteers [ Time Frame: Estimated average of 3 hours ]Biodistribution of [18F]FTC-146 represented as Standardized Uptake Value max (SUVmax) in healthy volunteers.
- [18F]FTC-146 Biodistribution in Pain Patients [ Time Frame: Estimated average of 3 hours ]Biodistribution of [18F]FTC-146 represented as Standardized Uptake Value max (SUVmax) in pain patients.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Healthy Volunteers:
1. At least 18 years old.
Pain Patients:
- At least 18 years old.
- Chronic pain (nociceptive, neuropathic or mixed pain) lasting greater than 2 months.
- Pain level of at least 4/10 on a 0-10 Comparative Pain Scale.
Exclusion Criteria:
Healthy Volunteers:
- Pain
- Pain Medication
- MRI incompatible
- Pregnant or nursing
- Non-English speaker
Pain Patients:
- MRI incompatible
- Pregnant or nursing
- Non-English speaker

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03556137
Contact: Sandip Biswal, MD | (650) 498-4561 | biswal@stanford.edu | |
Contact: Sunyoung Park | sydoit@stanford.edu |
United States, California | |
Stanford University | Recruiting |
Stanford, California, United States, 94305 | |
Contact: Sunyoung Park, BA sydoit@stanford.edu | |
Principal Investigator: Sandip Biswal, MD |
Principal Investigator: | Sandip Biswal, MD | Stanford University Department of Radiology |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Sandip Biswal, Associate Professor of Radiology, Stanford University |
ClinicalTrials.gov Identifier: | NCT03556137 |
Other Study ID Numbers: |
45332 |
First Posted: | June 14, 2018 Key Record Dates |
Last Update Posted: | July 2, 2021 |
Last Verified: | June 2021 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
PET/MRI Chronic Pain |
Neuralgia Chronic Pain Nociceptive Pain Pain |
Neurologic Manifestations Peripheral Nervous System Diseases Neuromuscular Diseases Nervous System Diseases |